Bridgewater Associates LP Purchases 47,638 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Bridgewater Associates LP raised its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 54.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 135,186 shares of the company’s stock after buying an additional 47,638 shares during the quarter. Bridgewater Associates LP owned 0.13% of Neurocrine Biosciences worth $15,576,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Plato Investment Management Ltd increased its stake in Neurocrine Biosciences by 2,481.9% in the third quarter. Plato Investment Management Ltd now owns 10,973 shares of the company’s stock valued at $1,263,000 after acquiring an additional 10,548 shares during the period. Swiss National Bank grew its stake in shares of Neurocrine Biosciences by 1.4% in the 3rd quarter. Swiss National Bank now owns 298,700 shares of the company’s stock valued at $34,416,000 after purchasing an additional 4,100 shares during the period. KBC Group NV grew its stake in shares of Neurocrine Biosciences by 78.3% in the 3rd quarter. KBC Group NV now owns 18,972 shares of the company’s stock valued at $2,186,000 after purchasing an additional 8,332 shares during the period. Tidal Investments LLC raised its holdings in shares of Neurocrine Biosciences by 57.8% in the 1st quarter. Tidal Investments LLC now owns 9,542 shares of the company’s stock worth $1,316,000 after buying an additional 3,497 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of Neurocrine Biosciences during the 2nd quarter worth approximately $5,848,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on NBIX shares. JPMorgan Chase & Co. upped their price target on Neurocrine Biosciences from $173.00 to $181.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Guggenheim upped their target price on shares of Neurocrine Biosciences from $170.00 to $180.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Jefferies Financial Group lifted their price target on shares of Neurocrine Biosciences from $177.00 to $189.00 and gave the company a “buy” rating in a report on Monday, August 19th. Oppenheimer boosted their price target on shares of Neurocrine Biosciences from $216.00 to $219.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Finally, Royal Bank of Canada dropped their price objective on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a report on Friday, October 4th. Five research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $163.91.

Neurocrine Biosciences Stock Down 1.0 %

NASDAQ:NBIX opened at $126.59 on Thursday. The stock’s fifty day simple moving average is $118.97 and its 200-day simple moving average is $131.71. The firm has a market capitalization of $12.82 billion, a P/E ratio of 33.94 and a beta of 0.35. Neurocrine Biosciences, Inc. has a 12-month low of $110.81 and a 12-month high of $157.98.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.